The curative effect and safety of icotinib hydrochloride in the treatment of advanced non-small cell lung cancer / 中国基层医药

ABSTRACT

Objective To explore the effect of icotinib hydrochloride in the treatment of advanced non-small cell lung cancer (NSCLC).Methods 52 patients with advanced NSCLC were selected as the research subjects,and they were divided into conventional group and study group by the computer random grouping method,26 cases in each group.The conventional group took docetaxel treatment,and the study group took icotinib hydrochloride treatment.The treatment effect of the two groups was compared.Results The disease control rate of the study group was 84.62％,which was significantly higher than 57.69％ of the conventional group,the difference was statistically significant(x2 =4.591,P =0.032).The progression free survival of the study group was (5.54 ±0.23)months,which was longer than (4.52 ± 0.22) months of the conventional group,the difference was statistically significant (t =16.341,P =0.000).The incidence rate of adverse reaction of the study group was 23.08％,which was significantly lower than 50.00％ of the conventional group,the difference was statistically significant(x2 =4.063,P =0.044).Conclusion The effect of icotinib hydrochloride in the treatment of advanced NSCLC is distinct,and drug safety is relatively high,it can help prolong survival of patients,and it is worthy of popularizing practice.